Search

everythinglearnresearchcommunity

for

Search:↓

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Baricitinib is effective in promoting hair growth in severe alopecia areata.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Baricitinib for alopecia areata may rarely cause eye issues like keratitis.

Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.

Iressa often causes skin issues like acne and dryness in lung cancer patients.

Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

Baricitinib was effective in treating both early and late onset alopecia areata.

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

Disrupting the Flcn gene in mice causes early kidney cysts and tumors, which can be treated with rapamycin.

SCD-153 shows promise as an effective topical treatment for alopecia areata.

Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.

Topical JAK inhibitors may help children with alopecia areata regrow hair.

Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

A new microneedle patch effectively promotes hair regrowth with less frequent dosing.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.